Clinical trial • Phase IV • Immunology | Endocrinology

IMEROPRUBART for Graves' Disease

Phase IV trial of IMEROPRUBART for Graves' Disease. None/Not specified-controlled. 244 participants.

Overview

Trial Therapeutic Area
Immunology | Endocrinology
Trial Disease
Graves' Disease
Trial Stage
Phase IV
Drug Modality
Monoclonal antibody

Key dates

Initial CTIS Submission Date
20-01-2026
First CTIS Authorization Date
05-05-2026

Trial design

None/Not specified-controlled Phase IV trial in Belgium, Bulgaria, Czechia and others.

Comparator
None/Not specified
Target Sample Size
244
Trial Duration For Participant
364

Eligibility

Recruits 244 No vulnerable populations selected (isVulnerablePopulationSelected=false)..

Vulnerable Population
No vulnerable populations selected (isVulnerablePopulationSelected=false).

Inclusion criteria

  • {"criterion_text":"- Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503."}

Exclusion criteria

  • {"criterion_text":"- Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Percentage of Group A Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52]","definition_or_measurement_approach":"Assessed as the percentage of Group A participants who remain euthyroid, off anti-thyroid drugs (ATD), and off IMVT-1402 at Week 52."}

Secondary endpoints

  • {"endpoint_text":"- Percentage of Group A Participants who are euthyroid and off ATD [Time Frame: At Week 26]","definition_or_measurement_approach":"Assessed as the percentage of Group A participants who are euthyroid and not taking ATD at Week 26."}
  • {"endpoint_text":"- Percentage of Group A Participants who are euthyroid and off ATD [Time Frame: Up to Week 52]","definition_or_measurement_approach":"Assessed as the percentage of Group A participants who are euthyroid and off ATD up to Week 52."}
  • {"endpoint_text":"- Percentage of Group A Participants who are euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52]","definition_or_measurement_approach":"Assessed as the percentage of Group A participants who are euthyroid, off ATD, and off IMVT-1402 up to Week 52."}
  • {"endpoint_text":"- Time to earliest date of euthyroidism, off ATD, and off IMVT-1402 to the earliest date of confirmed relapse in Group A Participants [Time Frame: Up to Week 52]","definition_or_measurement_approach":"Time-to-event measured from earliest date of euthyroidism (off ATD and off IMVT-1402) to earliest date of confirmed relapse in Group A, up to Week 52."}
  • {"endpoint_text":"- Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52]","definition_or_measurement_approach":"Assessed as the percentage of Group B participants who remain euthyroid, off ATD, and off IMVT-1402 up to Week 52."}
  • {"endpoint_text":"- Percentage of Group B Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52]","definition_or_measurement_approach":"Assessed as the percentage of Group B participants who remain euthyroid, off ATD, and off IMVT-1402 at Week 52."}
  • {"endpoint_text":"- Time from Week 0 to the earliest date of confirmed relapse in Group B Participants [Time Frame: Up to Week 52]","definition_or_measurement_approach":"Time-to-event from Week 0 to earliest confirmed relapse in Group B, up to Week 52."}
  • {"endpoint_text":"- Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: Up to Week 52]","definition_or_measurement_approach":"Assessed as the percentage of Group C participants who remain euthyroid, off ATD, and off IMVT-1402 up to Week 52."}
  • {"endpoint_text":"- Percentage of Group C Participants who remain euthyroid, off ATD, and off IMVT-1402 [Time Frame: At Week 52]","definition_or_measurement_approach":"Assessed as the percentage of Group C participants who remain euthyroid, off ATD, and off IMVT-1402 at Week 52."}
  • {"endpoint_text":"- Time From Week 0 to the earliest date of confirmed relapse in Group C Participants [Time Frame: Up to Week 52]","definition_or_measurement_approach":"Time-to-event from Week 0 to earliest confirmed relapse in Group C, up to Week 52."}
  • {"endpoint_text":"- Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for TRAb [Time Frame: At Week 26]","definition_or_measurement_approach":"Assessed as the percentage of Group A participants who are euthyroid, off ATD, and TRAb-seronegative at Week 26."}
  • {"endpoint_text":"- Percentage of Group A Participants who are euthyroid, off ATD, and seronegative for TRAb [Time Frame: Up to Week 52]","definition_or_measurement_approach":"Assessed as the percentage of Group A participants who are euthyroid, off ATD, and TRAb-seronegative up to Week 52."}

Recruitment

Planned Sample Size
244
Recruitment Window Months
46
Consent Approach
Informed consent obtained from participants. Multiple country- and language-specific informed consent (SIS/ICF) documents are provided (examples: EN, BG, DE, FR, NL, ES, IT, HU, LV, PL, EL, CZ) and there are template ICFs for pregnant partners, caregivers and scouts; no separate assent process is described in the available records.

Geography

Total Number Of Sites
93
Total Number Of Participants
128

Belgium

Earliest CTIS Part Ii Submission Date
10-04-2026
Latest Decision Or Authorization Date
06-05-2026
Processing Time Days
26
Number Of Sites
2
Number Of Participants
4

Sites

Site Name
Hopital Erasme
Department Name
Division of Endocrinology
Contact Person Name
Aglaia Kyrilli
Contact Person Email
aglaia.kyrilli@hubruxelles.be
Site Name
AZ ST-JAN Brugge A.V.
Department Name
Internal Medicine / Endocrinology
Contact Person Name
Annick Van den Bruel

Bulgaria

Earliest CTIS Part Ii Submission Date
10-04-2026
Latest Decision Or Authorization Date
11-05-2026
Processing Time Days
31
Number Of Sites
14
Number Of Participants
17

Sites

Site Name
Medcenter Nova Clinic Ltd.
Contact Person Name
Gergana Marinova
Contact Person Email
gergana_tosheva@abv.bg
Site Name
Alexandrovska University Hospital
Department Name
Clinic of Endocrinology and Metabolic Diseases
Contact Person Name
Zdravko Kamenov
Contact Person Email
zkamenov@hotmail.com
Site Name
Diagnostic Consultative Center Equita OOD
Contact Person Name
Neli Klyuchkova
Contact Person Email
klychkova@gmail.com
Site Name
University Multiprofile Hospital For Active Treatment Sofiamed OOD
Department Name
Clinic of Endocrinology and Metabolic Diseases
Contact Person Name
Anna-Maria Borissova Ivanova
Contact Person Email
anmarbor@abv.bg
Site Name
Medical Centre Pratia Clinic EOOD
Contact Person Name
Artin Magardichyan
Site Name
University Specialized Hospital For Active Treatment In Endocrinology Akad. Iv. Penchev EAD
Department Name
Third Clinic of Endocrinology and Metabolic Diseases
Contact Person Name
Roussanka Kovatcheva
Contact Person Email
roussanka_kov@yahoo.com
Site Name
Medical Center Viva Phoenix OOD
Contact Person Name
Kaloyan Velkov
Contact Person Email
kaloyanvelkov@gmail.com
Site Name
Multiprofile Hospital For Active Treatment Hadji Dimitar OOD
Department Name
Department of Endocrinology and Metabolic Diseases
Contact Person Name
Farah Ghassan
Contact Person Email
gasan_farah@mail.bg
Site Name
Medical Center Smolyan Klinikal Research Ltd.
Contact Person Name
Emiliya Apostolova
Contact Person Email
vitamed@abv.bg
Site Name
Medical Center Berbatov Ltd.
Contact Person Name
Dimitar Berbatov
Contact Person Email
dr.berbatov@gmail.com
Site Name
Kalimat Medical Center Ltd.
Contact Person Name
Mariana Yoncheva-Mihaylova
Contact Person Email
mdyoncheva@gmail.com
Site Name
Multiprofile Hospital For Active Treatment Knyaginya Klementina Sofia EAD
Department Name
Department of Endocrinology and Metabolic Diseases
Contact Person Name
Ivaylo Lefterov
Contact Person Email
ilefterov@abv.bg
Site Name
University Multiprofile Hospital For Active Treatment Pulmed Ltd.
Department Name
Department of Endocrinology and Metabolic Diseases at Clinic of Internal Diseases
Contact Person Name
Mitkov Mitko
Contact Person Email
mitko_mitkov@yahoo.com
Site Name
University Multiprofile Hospital For Active Treatment Kaspela EOOD
Department Name
Clinic of Endocrinology and Metabolic Diseases
Contact Person Name
Boyan Nonchev
Contact Person Email
nonchev_md@abv.bg

Czechia

Earliest CTIS Part Ii Submission Date
02-02-2026
Latest Decision Or Authorization Date
05-05-2026
Processing Time Days
92
Number Of Sites
4
Number Of Participants
6

Sites

Site Name
Edumed s.r.o.
Contact Person Name
Alicia Veselá
Contact Person Email
alica.vesela@edu-med.cz
Site Name
Milan Kvapil s.r.o.
Department Name
Diabetologická ambulance
Contact Person Name
František Loos
Contact Person Email
frankyloos@gmail.com
Site Name
Endokrinologie Klanovice s.r.o.
Contact Person Name
Markéta Weichetová
Contact Person Email
m.weichetova@post.cz
Site Name
ResTrial s.r.o.
Department Name
Klinika ResTrial
Contact Person Name
Emília Malicherová

Germany

Earliest CTIS Part Ii Submission Date
02-02-2026
Latest Decision Or Authorization Date
11-05-2026
Processing Time Days
98
Number Of Sites
5
Number Of Participants
9

Sites

Site Name
Medicover Medizin gGmbH
Department Name
Medizinische Klinik und Poliklinik IV
Contact Person Name
Guenter Stalla
Contact Person Email
Guenter.Stalla@medicover.de
Site Name
Medical Center - University Of Freiburg
Department Name
Medizinische Klinik II, Gastroenterologie, Hepatologie, Infektiologie and Endokrinologie
Contact Person Name
Jochen Seufert
Site Name
Technische Universitaet Dresden
Department Name
Department of Medicine III, Devision of Endocrinology, Diabetes and Bone diseases
Contact Person Name
Lorenz Hofbauer
Site Name
HELIOS Kliniken Schwerin GmbH
Department Name
Internal Medecine, Endocrinology, Diabetology
Contact Person Name
Urs Lichtenauer
Site Name
Universitaetsklinikum Wuerzburg AöR
Department Name
Medizinische Klinik I, Endokrinologie
Contact Person Name
Ulrich Dischinger
Contact Person Email
dischinger_u@ukw.de

Greece

Earliest CTIS Part Ii Submission Date
02-02-2026
Latest Decision Or Authorization Date
07-05-2026
Processing Time Days
94
Number Of Sites
4
Number Of Participants
4

Sites

Site Name
General Hospital Of Athens Alexandra
Department Name
Endocrine Department and Diabetological Center
Contact Person Name
Vasiliki Vasileiou
Contact Person Email
vasvasendo@gmail.com
Site Name
Evaggelismos Hospital
Department Name
Department of Endocrinology "D.IKKOS"
Contact Person Name
Marinella Tzanela
Contact Person Email
endo.evangelismos@gmail.com
Site Name
Ippokratio General Hospital Of Thessaloniki
Department Name
Department of Endocrinology, Diabetes & Metabolism
Contact Person Name
Fotini Adamidou
Contact Person Email
fotini.adamidou@gmail.com
Site Name
Laiko General Hospital Of Athens
Department Name
1st department of internal medecine, Endocrinology Unit
Contact Person Name
Anna Angelousi
Contact Person Email
a.angelousi@gmail.com

Hungary

Earliest CTIS Part Ii Submission Date
17-03-2026
Latest Decision Or Authorization Date
11-05-2026
Processing Time Days
55
Number Of Sites
6
Number Of Participants
18

Sites

Site Name
University Of Debrecen
Department Name
Internal Medicine Clinic, Endocrinology
Contact Person Name
Miklos Bodor
Contact Person Email
bodor.miklos@med.unideb.hu
Site Name
Obudai Egeszseguegyi Centrum Kft.
Contact Person Name
István Páll
Contact Person Email
istvan.pall@oec.hu
Site Name
Semmelweis University
Department Name
Department of Internal Medicine and Oncology
Contact Person Name
István Takacs
Contact Person Email
takacs.istvan@semmelweis.hu
Site Name
Trial Pharma Kft.
Department Name
Endocrinology
Contact Person Name
Tivadar Banyai
Contact Person Email
banyai.tivadar@bmkk.eu
Site Name
University Of Pecs
Department Name
Clinical Center, 1st Department of Internal Medicine, Department of Endocrinology and Metabolism
Contact Person Name
Emese Mezosi
Contact Person Email
mezosi.emese@pte.hu
Site Name
University Of Szeged
Department Name
Clinical Center, Internal Medicine Clinic, Endocrinology
Contact Person Name
Zsuzsanna Valkusz

Italy

Earliest CTIS Part Ii Submission Date
14-04-2026
Latest Decision Or Authorization Date
06-05-2026
Processing Time Days
22
Number Of Sites
22
Number Of Participants
16

Sites

Site Name
Azienda Ospedaliera Universitaria Federico II Di Napoli
Department Name
DIPARTIMENTO DI SANITA' PUBBLICA
Contact Person Name
Domenico Salvatore
Contact Person Email
domsalva@unina.it
Site Name
Ospedale San Raffaele S.r.l.
Department Name
Endocrinology Department
Contact Person Name
Andrea Giustina
Contact Person Email
Giustina.andrea@hsr.it
Site Name
Azienda Sanitaria Universitaria Friuli Centrale
Department Name
Oncology Area Department
Contact Person Name
Jacopo Manso
Site Name
Azienda Ospedaliera Ospedale Di Circolo E Fondazione Macchi
Department Name
SC Endocrinologia
Contact Person Name
Maria Laura Piera Tanda
Contact Person Email
marialaura.tanda@uninsubria.it
Site Name
Hospital Santa Maria Della Misericordia
Department Name
Medicine and Surgery
Contact Person Name
Efisio Puxeddu
Contact Person Email
efisio.puxeddu@unipg.it
Site Name
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
Department Name
SC Malattie Endocrine-Diabetologia
Contact Person Name
Silvia Ippolito
Contact Person Email
sippolito@asst-pg23.it
Site Name
Istituti Clinici Scientifici Maugeri S.p.A.
Department Name
Unit of Endocrinology and Metabolic Diseases
Contact Person Name
Mario Rotondi
Contact Person Email
Mario.rotondi@icsmaugeri.it
Site Name
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Department Name
Unit of Endocrinology
Contact Person Name
Mario Salvi
Contact Person Email
mario@mariosalvinet.it
Site Name
Azienda Ospedaliero-Universitaria Sant Andre
Department Name
UOC Medicina Specialistica Endocrino-Metabolica
Contact Person Name
Salvatore Monti
Contact Person Email
salvatore.monti@uniroma1.it
Site Name
Azienda Unita' Sanitaria Locale Toscana Nord Ovest
Department Name
U.O. Aziendale di Endocrinologia
Contact Person Name
Daniele Barbaro
Site Name
Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
Department Name
Dipartimento di Medicinina Generale e Specilistica
Contact Person Name
Gianluca Aimaretti
Contact Person Email
Gianluca.aimaretti@unito.it
Site Name
Azienda Ospedaliero-Universitaria Senese
Department Name
Medical Sciences
Contact Person Name
Maria Grazia Castagna
Contact Person Email
mariagrazia.castagna@unisi.it
Site Name
Azienda Ospedaliero Universitaria Pisana
Department Name
UO Endocrinologia II
Contact Person Name
Michele Marino
Contact Person Email
michele.marino@med.unipi.it
Site Name
Azienda Ospedaliero-Universitaria Policlinico Umberto I
Department Name
Department of Experimental Medicine, Sapienza University of Rome
Contact Person Name
Elisa Giannetta
Contact Person Email
Elisa.giannetta@uniroma1.it
Site Name
Azienda Ospedaliero-Universitaria Di Cagliari
Department Name
U.O Endocrinologia
Contact Person Name
Giulia Lanzolla
Contact Person Email
giulia.lanzolla@unica.it
Site Name
Istituto Auxologico Italiano
Department Name
Endocrinologia e Malattie del Metabolismo
Contact Person Name
Luca Persani
Contact Person Email
luca.persani@unimi.it
Site Name
Azienda Ospedaliera Di Rilievo Nazionale Antonio Cardarelli
Department Name
UoC endocrinologia
Contact Person Name
Francesco Scavuzzo
Site Name
Azienda Ospedaliera Santa Croce E Carle
Department Name
Endocrinology
Contact Person Name
Federico Arecco
Contact Person Email
arecco.f@ospedale.cuneo.it
Site Name
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Department Name
UOC Malattie Endocrine, del ricambio e della nutrizione
Contact Person Name
Giorgio Arnaldi
Site Name
Universita Humanitas
Department Name
Department of Biomedical Sciences
Contact Person Name
Andrea Gerardo Antonio Lania
Contact Person Email
Andrea.lania@humanitas.it
Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department Name
Endocrinologia
Contact Person Name
Andrea Pontecorvi
Contact Person Email
Alfredo.pontecorvi@unicatt.it
Site Name
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Department Name
U.O.C. Endocrinologia e prevenzione e cura del diabete
Contact Person Name
Uberto Pagotto
Contact Person Email
uberto.pagotto@unibo.it

Latvia

Earliest CTIS Part Ii Submission Date
13-04-2026
Latest Decision Or Authorization Date
06-05-2026
Processing Time Days
23
Number Of Sites
6
Number Of Participants
7

Sites

Site Name
Daces Teterovskas arsta prakse endokrinologija SIA
Contact Person Name
Dace Teterovska
Contact Person Email
dace.fonds@inbox.lv
Site Name
Riga East University Hospital
Department Name
Clinical Centre "Bikernieki", Ophthalmology clinic
Contact Person Name
Kristine Baumane
Contact Person Email
baumanek@ml.lv
Site Name
Veselibas un socialas aprupes klinika APS SIA
Department Name
Endocrinology
Contact Person Name
Lelde Krüzmane
Contact Person Email
lelde.kruzmane@gmail.com
Site Name
Ziemelkurzemes regionala slimnica SIA
Department Name
Ophthalmology
Contact Person Name
Kaspars Ozols
Contact Person Email
mr.kaspars.ozols@gmail.com
Site Name
Pauls Stradins Clinical University Hospital
Department Name
Center of Endrocrinology
Contact Person Name
Kristine Geldnere
Contact Person Email
kristineab@inbox.lv
Site Name
Siguldas Slimnica
Department Name
Outpatient Department
Contact Person Name
Renate Helda
Contact Person Email
slimnica@siguldasslimnica.lv

Spain

Earliest CTIS Part Ii Submission Date
26-02-2026
Latest Decision Or Authorization Date
07-05-2026
Processing Time Days
70
Number Of Sites
8
Number Of Participants
13

Sites

Site Name
Hospital Clinic De Barcelona
Department Name
Nutrition and endocrinology
Contact Person Name
Mireia Mora
Contact Person Email
mporta@clinic.cat
Site Name
Hospital Germans Trias I Pujol
Department Name
Endocrinology
Contact Person Name
Federico Vázquez
Site Name
Hospital Universitario De La Princesa
Department Name
Endocrinology
Contact Person Name
Monica Marazuela
Site Name
Hospital Clinico San Carlos
Department Name
Servicio de Endocrinología, Metabolismo y Nutrición
Contact Person Name
Maria del Carmen MONTAÑEZ ZORRILLA
Site Name
Hospital Universitario Virgen De Las Nieves
Department Name
Endocrinology
Contact Person Name
Martin López de la Torre Casares
Contact Person Email
martinendocrino@gmail.com
Site Name
Hospital Universitari Vall D Hebron
Department Name
Endocrinology and Nutrition
Contact Person Name
Alejandra Planas Vilaseca
Contact Person Email
alejandraplanas04@gmail.com
Site Name
Hospital Universitario Virgen De La Macarena
Department Name
Ophtalmology
Contact Person Name
Antonio Garrido
Contact Person Email
gaherfamily@hotmail.com
Site Name
Hospital Universitario Reina Sofia
Department Name
Endocrinology
Contact Person Name
Maria Angeles Galvez Moreno

Netherlands

Earliest CTIS Part Ii Submission Date
17-04-2026
Latest Decision Or Authorization Date
08-05-2026
Processing Time Days
21
Number Of Sites
4
Number Of Participants
2

Sites

Site Name
Ikazia Ziekenhuis
Department Name
Internal medicine
Contact Person Name
Carolien Beukhof
Contact Person Email
c.beukhof@ikazia.nl
Site Name
Albert Schweitzer Ziekenhuis
Contact Person Name
Simone Cornelia Christina Hartong
Contact Person Email
s.c.c.hartong@asz.nl
Site Name
Maasstad Ziekenhuis Stichting
Department Name
Internal Medicine
Contact Person Name
Charlotte van Noord
Contact Person Email
noordc@maasstadziekenhuis.nl
Site Name
Sint Franciscus Vlietland Groep Stichting
Department Name
Internal Medicine
Contact Person Name
Kim Van Der Weerd
Contact Person Email
k.weerd@franciscus.nl

Poland

Earliest CTIS Part Ii Submission Date
10-04-2026
Latest Decision Or Authorization Date
08-05-2026
Processing Time Days
28
Number Of Sites
18
Number Of Participants
32

Sites

Site Name
Centrum Medyczne Hope Clinic Sebastian Szklener
Contact Person Name
Marcin Lewicki
Contact Person Email
lewicki-marcin@wp.pl
Site Name
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
Department Name
Centrum Diabetologiczne Kliniki Chorób Wewnętrznych, Endokrynologii i Diabetologii
Contact Person Name
Edward Franek
Contact Person Email
edward.franek@pimmswia.gov.pl
Site Name
Clinical Best Solutions Sp. z o.o. S.K.
Contact Person Name
Jolanta Patro-Malysza
Contact Person Email
jolapatro@wp.pl
Site Name
Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu
Department Name
Klinika Endokrynologii i Chorób Wewnętrznych
Contact Person Name
Marek Bolanowski
Contact Person Email
marek.bolanowski@umw.edu.pl
Site Name
Med Polonia Sp. z o.o.
Department Name
Dział badań klinicznych
Contact Person Name
Grzegorz Konieczny
Contact Person Email
gkonieczny78@gmail.com
Site Name
Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.
Department Name
Etyka Ośrodek Badań Klinicznych
Contact Person Name
Wojciech Matuszewski
Site Name
Diab Serwis Popenda Sp. j.
Contact Person Name
Grażyna Popenda
Site Name
Ośrodek Medyczny “Osteomed”
Contact Person Name
Mirosław Szlachcic
Contact Person Email
m.szlachcic@medistica.com.pl
Site Name
Eb Group Sp. z o.o.
Department Name
Centrum Zdrowia MDM
Contact Person Name
Tomasz Bednarczuk
Contact Person Email
tomasz.bednarczuk@wum.edu.pl
Site Name
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Department Name
Zakład Medycyny Nuklearnej i Endokrynologii Onkologicznej Centrum Wsparcia Badań Klinicznych
Contact Person Name
Barbara Jarząb
Contact Person Email
barbara.jarzab@io.gliwice.pl
Site Name
Uniwersytecki Szpital Kliniczny W Bialymstoku
Department Name
Klinika Endokrynologii, Diabetologii i Chorób Wewnętrznych
Contact Person Name
Katarzyna Siewko
Contact Person Email
katarzyna.siewko@umb.edu.pl
Site Name
Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Kielcach
Department Name
Klinika Endokrynologii
Contact Person Name
Aldona Kowalska
Site Name
Trialmed Sp. z o.o.
Department Name
Clinical Trials
Contact Person Name
Iwona Kaczor-Zboj
Contact Person Email
ikz@trialmed.pl
Site Name
Centrum Medyczne Intercor Sp. z o.o.
Contact Person Name
Roman Junik
Contact Person Email
intercor@farmepo.com
Site Name
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie
Department Name
Oddział Kliniczny Endokrynologii, Endokrynologii Onkologicznej, Med Nuklearnej i Chorób Wewnętrznych
Contact Person Name
Grzegorz Sokolowski
Contact Person Email
Grzegsok@gmail.com
Site Name
Uniwersyteckie Centrum Stomatologii I Medycyny Specjalistycznej Sp. z o.o.
Department Name
Poradnia Internistyczn
Contact Person Name
Marek Ruchala
Contact Person Email
mruchala@ump.edu.pl
Site Name
Clinicly Sp. z o.o.
Department Name
Centrum Medyczne Clinicly
Contact Person Name
Agata Bronisz
Contact Person Email
agata.bronisz.opole@gmail.com
Site Name
Reumed Sp. z o.o.
Department Name
Poradnia endokrynologicz na i diabetologiczna
Contact Person Name
Agnieszka Zwolak
Contact Person Email
zwolakag@wp.pl

Sponsor

Primary sponsor

Full Name
Immunovant Sciences GmbH
Organisation Type
Pharmaceutical company
Country Of Registered Address
Switzerland

Contract research organisations

Name
Icon Clinical Research Limited
Responsibilities
code 1; code 15: Equipment, Translations, Print Services; code 2; code 5; (also listed with code 4 in another entry)
Name
PRA Hellas CRO A.E.
Responsibilities
code 1
Name
Pharmaceutical Research Associates Group B.V.
Responsibilities
code 4
Name
Syneos Health Clinique Inc.
Responsibilities
code 4
Name
Scout Clinical
Responsibilities
code 15: Patient reimbursement services

Third parties

  • {"country":"United States","full_name":"Primevigilance USA Inc.","duties_or_roles":"code 8","organisation_type":"Pharmaceutical company"}
  • {"country":"Ireland","full_name":"Icon Clinical Research Limited","duties_or_roles":"code 1; code 15: Equipment, Translations, Print Services; code 2; code 5","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Avantor Inc.","duties_or_roles":"code 15: Long-term storage","organisation_type":"Pharmaceutical company"}
  • {"country":"Netherlands","full_name":"Pharmaceutical Research Associates Group B.V.","duties_or_roles":"code 4","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Suvoda LLC","duties_or_roles":"code 15: Packaging, Labelling and Distribution","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United States","full_name":"Medidata Solutions Inc.","duties_or_roles":"code 7","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"Ireland","full_name":"Icon Clinical Research Limited (duplicate entry)","duties_or_roles":"code 4","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Eclinical Solutions LLC","duties_or_roles":"code 6","organisation_type":"Pharmaceutical company"}
  • {"country":"Greece","full_name":"PRA Hellas CRO A.E.","duties_or_roles":"code 1","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Fisher Clinical Services Inc.","duties_or_roles":"code 14","organisation_type":"Pharmaceutical company"}
  • {"country":"Germany","full_name":"Fisher Clinical Services GmbH (Weil Am Rhein)","duties_or_roles":"code 14","organisation_type":"Pharmaceutical company"}
  • {"country":"Germany","full_name":"Fisher Clinical Services GmbH (Rheinfelden)","duties_or_roles":"code 14","organisation_type":"Pharmaceutical company"}
  • {"country":"Canada","full_name":"Syneos Health Clinique Inc.","duties_or_roles":"code 4","organisation_type":"Hospital/Clinic/Other health care facility"}
  • {"country":"United States","full_name":"Scout Clinical","duties_or_roles":"code 15: Patient reimbursement services","organisation_type":"Hospital/Clinic/Other health care facility"}
  • {"country":"France","full_name":"Voisin Consulting Life Sciences","duties_or_roles":"code 12","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Clinical Ink Inc.","duties_or_roles":"code 15: Ediary; code 7","organisation_type":"Pharmaceutical company"}
  • {"country":"France","full_name":"Voisin Consulting Life Sciences (duplicate?)","duties_or_roles":"code 12","organisation_type":"Pharmaceutical company"}
  • {"country":"","full_name":"Other listed third parties (multiple organisations for distribution, storage and logistics including Fisher Clinical Services GmbH entries, Avantor Inc., etc.)","duties_or_roles":"","organisation_type":""}

Investigational products

Investigational Product Name
IMVT-1402
Active Substance
IMEROPRUBART
Modality
Monoclonal antibody
Routes Of Administration
Subcutaneous
Route
Subcutaneous
Maximum Dose
600 mg per day

Related trials

Other published trials that may interest you.